Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Reversing cardiac hypertrophy and heart failure using a cardiac targeting peptide linked to miRNA106a
Lü, Ming , Cai, Siqi , Korolowicz, Kyle , Deng, Claire, Taskintuna, Kaan, Yurko, Ray, Islam, Kazi , Schoonover, Bryn, Lopuszynski, Jack , Wang, Hongkun , Gallicano, G. Ian , Lopuszynski, Jack B, Gallicano, G Ian , Cai, Siqi, Ahern, Gerard P. , Zahid, Maliha

Mayo Clinic

Clinical and Translational Medicine | August 18, 2025 | Volume: 15 | Issue: 8 | Pages: No page available

10.1002/ctm2.70432 | PMID 40820483 Get It

Abstract Background One in five adults aged 40 will develop heart failure (HF) during their lifetime. Risk factors (e.g., hypertension, diabetes mellitus, coronary artery disease, etc.) lead to structural and functional changes in cardiomyocytes, resulting in HF. At the cellular level, these changes consist of mis/over‐expression of genes that regulate cardiac identity (e.g., CamK2δ, PKC, Stat3, etc.). The current paradigm for treating HF is pharmacological or device‐based intervention; however, with few exceptions, the condition worsens with time. We are proposing to implement a change in HF treatment, shifting from a drug‐centric system to a cardiac target‐specific molecular approach that would reverse hypertrophy and adverse remodelling of affected cardiomyocytes. Methods A cardiomyocyte targeting peptide (CTP) was reversibly linked to miRNA106a for delivery to a mouse model of HF. Reversal of morphological, signalling, and physiological HF parameters was measured. Additionally, CTP‐miRNA106a was introduced into a human cardiomyocyte cell line to identify mechanism(s) at play for reversing HF characteristics (e.g., hypertrophy). Results Bio‐distribution studies showed that intravenously injected CTP‐miRNA106 delivered its cargo specifically to the heart within 30 min, followed by clearance of CTP from the heart to the kidneys, and to a lesser extent, the liver by 35 h with persistence of miRNA106a in cardiomyocytes until day 7 (the latest tested time‐point). CTP‐miRNA106a reversed angiotensin2/isoproterenol‐induced hypertrophy in 90% of the treated mice. We also identified two potential HF intracellular signalling pathways/mechanisms (PLCβ1/PKC/IP3 and NF‐κB) targeted by CTP‐miRNA106a that could benefit many pathophysiologies underlying HF, including inflammation. Conclusions CTP‐miRNA106a, a first‐of‐a‐kind cardiac‐specific drug, downregulates genes involved in cardiac hypertrophy and inflammation through the PLCβ1 and CamKIIδ kinase pathways. CTP delivery of miRNA106a cargo is specific to cardiomyocytes both in vitro and in vivo, and once delivered, many HF parameters, including hypertrophy, are reversed. Key points Cardiac Targeting Peptide (CTP) delivers, specifically to the heart, reversibly linked miRNA106a. MiRNA106a targets genes in various pathways known to cause heart failure when they are over/hyper activated returning their expression to normal levels. In vivo analyses using a mouse heart failure model resulted in reversal of heart failure parameters in 19/20 mice.
Camidanlumab tesirine for relapsed or refractory classic Hodgkin lymphoma: a phase 2 study
Herrera, Alex F. , Ansell, Stephen M. , Zinzani, Pier Luigi , Maddocks, Kami J. , Pinto, Antonio , Collins, Graham P. , Bachanová, Veronika , Bartlett, Nancy L. , Bence‐Bruckler, Isabelle , Mayer, Jiří , Advani, Ranjana H. , Feldman, Tatyana , Hess, Brian , Szomor, Árpád, André, Marc, Dyczkowski, Jerzy, Havenith, Karin , Toukam, Marie , Pantano, Serafino, Cruz, Hans G. , Wang, Luqiang, Negievich, Yanina, Lucero, Melanie , Wuerthner, Jens, Carlo‐Stella, Carmelo , Radford, John , Pinto, Antonio , Bartlett, Nancy L , Hamadani, Mehdi , Savage, Kerry J , Casasnovas, René-Olivier , Iyengar, Sunil , Townsend, William , Cruz, Hans G , Carlo-Stella, Carmelo , Bachanova, Veronika , Zinzani, Pier Luigi , Advani, Ranjana H , Radford, John , Collins, Graham P., Hamadani, Mehdi , Kline, Justin Paul , Savage, Kerry J. , Caimi, Paolo F. , Casasnovas, Olivier , Bastos‐Oreiro, Mariana , Townsend, William

Mayo Clinic

Blood Advances | August 14, 2025 | Volume: 9 | Issue: 23 | Pages: 6205-6217

10.1182/bloodadvances.2024015600 | PMID 40811783 Get It

Abstract Outcomes in classic Hodgkin lymphoma (cHL) have steadily improved; however, additional therapies are needed for patients who relapse or do not respond to novel agents. Here, we report the efficacy and safety of camidanlumab tesirine (Cami), an anti-CD25 antibody-drug conjugate, in patients with relapsed/refractory cHL after brentuximab vedotin/programmed cell death protein 1 inhibitor therapies from the phase 2 ADCT-301-201 study. Eligible patients were adults with cHL who had received ≥3 previous lines of systemic therapy (or ≥2 if ineligible for hematopoietic stem cell transplant). Patients received 45 μg/kg Cami (IV, once every 3 weeks) in cycles 1 to 2, followed by 30 μg/kg IV once every 3 weeks for ≤1 year. The primary end point was overall response rate (ORR) per 2014 Lugano classification. Secondary end points included complete response rate (CRR), progression-free survival (PFS), and overall survival (OS). In total, 117 patients were enrolled with a median age of 37.0 years (range, 19-87). The ORR was 70.1% (95% confidence interval [CI], 60.9-78.2), with a CRR of 33.3% (95% CI, 24.9-42.6). The median PFS was 9.13 months (95% CI, 5.3-15.0); median OS was not reached. Thirty-three (28.2%) patients discontinued treatment because of treatment-emergent adverse events; the most common reasons were skin and subcutaneous tissue disorders (n = 10 [8.5%] patients), infections and infestations (n = 5 [4.3%]), and nervous systems disorders (n = 5 [4.3%]). Guillain-Barré–type or polyradiculopathy-type events occurred in 8 (6.8%) patients. Cami was efficacious in this heavily pretreated population; however, the efficacy was overshadowed by substantial issues with the safety profile. This trial was registered at www.clinicaltrials.gov as #NCT04052997.
Plasma proteomic analysis identifies proteins and pathways related to Alzheimer's risk
Huang, Yen-Ning , Liu, Shiwei , Park, Tamina, Chaudhuri, Soumilee , Carrasquillo, Minerva M. , Ertekin‐Taner, Nilüfer , Bice, Paula J. , Blennow, Kaj , Russ, Kristen A., Dage, Jeffrey L. , Brosch, Jared R. , Farlow, Martin R. , Clark, David G., Mathew, Sunu , Unverzagt, Frederick W. , Gao, Sujuan , Apostolova, Liana G. , Foroud, Tatiana, Risacher, Shannon L. , Nho, Kwangsik, Kuchenbecker, Lindsey A. , Dage, Jeffrey L , Carrasquillo, Minerva M. , Zetterberg, Henrik , Nudelman, Kelly , Cruchaga, Carlos , Wang, Sophia , Wilcock, Donna M. , Saykin, Andrew J.

Mayo Clinic

Alzheimer's & Dementia | August 14, 2025 | Volume: 21 | Issue: 8 | Pages: No page available

10.1002/alz.70579 | PMID 40810263 Get It

Abstract INTRODUCTION We investigated associations of plasma proteins with blood‐based amyloid/tau/neurodegeneration/inflammation (A/T/N/I) biomarkers for Alzheimer's disease (AD). METHODS Plasma proteomics and clinical data from the Indiana AD Research Center ( N = 498) were used. Association analysis of plasma proteins with blood A/T/N/I biomarkers as well as diagnosis was performed, followed by replication in an independent cohort ( N = 323), network analysis, pathway enrichment, and machine learning classification to identify proteins and pathways related to AD risk. RESULTS We identified 35 proteins associated with AD, 20 of which were replicated in the independent cohort. We identified 150, 448, and 219 proteins associated with T/N/I biomarkers, respectively, revealing biomarker‐specific pathways. Network analysis identified two modules associated with T/N/I biomarkers, preserved in cerebrospinal fluid (CSF), and their enriched pathways. The classification model of proteins effectively differentiated AD (area under the curve [AUC] = 0.930). CONCLUSION Our findings suggest dysregulated plasma proteins and pathways in AD, enhancing our understanding of molecular mechanisms and diagnostic strategies for AD. Highlights Plasma proteins were identified as being associated with Alzheimer's disease (AD) and plasma biomarkers. The identified proteins were replicated in both plasma and cerebrospinal fluid (CSF) proteomics. The identified proteins were associated with AD biomarker‐specific pathways. The identified proteins improved the performance of the AD classification. Protein network analysis identified network modules and their enriched pathways.
Caregiver experiences after the death of a person with dementia with Lewy bodies: A mixed-methods analysis
Armstrong, Melissa J. , Dai, Yunfeng , LaBarre, Brian , Wang, Tingchang , Sovich, Kaitlin , Jury, Hannah F , Henriquez, Adolfo M , Maixner, Susan M. , Paulson, Henry L. , Fields, Julie A. , Lunde, Angela , Manning, Carol A. , Taylor, Angela , Dai, Yunfeng , LaBarre, Brian , Wang, Tingchang , Jury, Hannah F , Henriquez, Adolfo M , Maixner, Susan M , Lunde, Angela M , Boeve, Brad , Baker, Zachary G , Paulson, Henry L , Armstrong, Melissa J , Wollney, Easton N. , Li, Zhigang , Galvin, James E. , Boeve, Bradley F.

Mayo Clinic

Journal of Alzheimer’s Disease | August 14, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/13872877251365218 | PMID 40808538 Get It

Background Dementia with Lewy bodies (DLB) is a common degenerative dementia, but no studies investigate bereaved caregiver experiences. Objective To investigate the experiences of caregivers three months after the death of persons with DLB using a mixed-methods approach. Methods Dyads of individuals with moderate-advanced DLB and their primary informal caregivers were followed prospectively every 6 months until the person with DLB died. Caregivers completed a study visit with questionnaires and a semi-structured interview ∼3 months later. Spearman correlation coefficients and Wilcoxon rank-sum tests evaluated the relationships of post-death measures with pre-death patient and caregiver variables. Thematic analysis was used to analyze the interviews. Results Seventy-three caregivers completed visits (mean 3.5 months post-death). Most of the caregivers were women (82.2%) and spouses (76.7%) or adult children (17.8%). Over 40% had scores indicating risk for clinical depression. Post-death caregiver experiences (depression, quality of life, grief, resilience) correlated with pre-death caregiver experiences. Post-death experiences did not associate with patient characteristics, disease-related symptoms, or healthcare services used in the last 6 months of life. Trajectories for caregiver measures from pre- to post-death visits varied widely. Interview themes included grief and sadness, anger, guilt and regret, relief, appreciation/gratitude, and adjusting to a new normal. Conclusions The finding that pre-death caregiving experiences have the strongest association with post-death experiences emphasizes the critical importance of accessible and evidence-based caregiver support before and after the death of a person with DLB. Research is needed to develop interventions for current and bereaved caregivers of individuals with DLB. Trial registration information NCT04829656 (submitted 2021-03-22).
Real-world clinical outcomes of cabozantinib as a second-line treatment for advanced hepatocellular carcinoma: a retrospective US claims analysis
Ahn, Daniel H. , Park, Noh Jin, Locker, Michael, Zhou, Zheng‐Yi , Wang, Travis , Yu, Shengsheng , Yu, Shengsheng , Nie, Xiaoyu

Mayo Clinic

The Oncologist | August 12, 2025 | Volume: 30 | Issue: 9 | Pages: No page available

10.1093/oncolo/oyaf252 | PMID 40795838 Get It

Abstract Background Cabozantinib is indicated for hepatocellular carcinoma (HCC) following first-line (1L) sorafenib, but the 1L standard has shifted to immuno-oncology (IO)-based regimens. This study evaluated real-world outcomes among patients with advanced HCC receiving second-line (2L) cabozantinib following 1L therapies, including newer regimens. Patients and Methods US claims data were used to identify adults with advanced HCC initiating 2L cabozantinib monotherapy (index date). Patients were stratified into three 1L treatment cohorts: IO monotherapy/IO + IO combination therapy; IO + non–IO combination therapy; or tyrosine kinase inhibitor (TKI) monotherapy. Real-world time to treatment discontinuation (rwTTD), real-world time to next treatment or death (rwTNTD), real-world overall survival (rwOS), and cabozantinib dosing were assessed collectively and by cohort. Adverse events were assessed before/after cabozantinib initiation. Results Among 148 patients who received 2L cabozantinib, 28 were in the IO monotherapy/IO + IO combination therapy cohort, 54 in the IO + non–IO combination therapy cohort, and 66 in the TKI monotherapy cohort. Median rwTTD among all patients was 3.2 months; median rwTNTD was 7.6 months; 12-month rwOS rate was 61.6%. There were no significant differences in these outcomes among the three cohorts. Overall, 44.6% of patients initiated 2L cabozantinib at 60 mg/day, of whom 39.4% required a dose reduction; 37.8% initiated at 40 mg/day, of whom 16.1% had a dose reduction. Adverse event rates were similar before/after cabozantinib initiation. Conclusions Cabozantinib shows consistent effectiveness and safety in the 2L HCC setting following prior TKIs or IO-based regimens in real-world clinical practice. These findings may inform 2L treatment decisions.
Real-world Monitoring of ctDNA Reliably Predicts Cancer Recurrence and Treatment Efficacy in Patients with Resected Stages I-III Colon Cancer
Cohen, Stacey A. , Aushev, Vasily N. , Nagarajan, Arun , Wang, Chongkai , Alyunis, Fadhel, Tejani, Mohamedtaki Abdulaziz, Alqahtani, Ali , Marshall, John C., Chang, Jeremy , Manage, Kevin, George, Giby V., Malhotra, Meenakshi , Chandana, Sreenivasa R , Mehler, Shoshana , Somer, Bradley G. , Babadi, Ellie, Hanna, Diana L. , Chidharla, Anusha , Kasi, Anup , Vosoughi, Elham , Briski, Robert , Azzi, Georges, Katiyar, Vatsala , Sharma, Vivek R. , Shreenivas, Aditya , Fuqua, Jacob , Malla, Midhun , Polite, Blasé N. , Bent, Alisha H., Liu, Minetta C. , Aleshin, Alexey , Cohen, Stacey A , Laliotis, George , Jabbal, Iktej Singh , Fakih, Marwan , Sharif, Saima , Botta, Gregory P. , George, Giby V., Sharma, Shruti , Wu, Christina N. , Dayyani, Farshid , Pedersen, Katrina S. , Chan, Abigail Sy , Chakrabarti, Sakti , Bent, Alisha , Rabinowitz, Matthew , Jurdi, Adham Adel , Kopetz, Scott

Mayo Clinic

Annals of Surgery | August 7, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/sla.0000000000006887 | PMID 40772634 Get It

Objective: In this study, we evaluate the utility of ctDNA analysis in a large cohort of patients for whom ctDNA testing was ordered commercially with real-world application. Summary Background Data: Circulating tumor DNA (ctDNA) has emerged as a prognostic and predictive biomarker for assessing post-surgical molecular residual disease (MRD) and response to treatment. Methods: A real-world data analysis was performed using commercial ctDNA testing (SignateraTM) from patients (N=795, n=5,971 plasma samples) with stage I-III colon cancer treated at multiple US institutions. The association of ctDNA detection within the MRD window, during surveillance, and the impact of ACT was correlated with patient outcomes. Results: ctDNA-positive patients during the MRD window and surveillance showed significantly shorter DFS compared to ctDNA-negative patients (hazard ratio (HR): 9.85, P<0.0001; HR: 26.91, P<0.0001). Multivariate analysis of the MRD window revealed ctDNA-positivity as the most significant factor associated with inferior DFS (adjHR: 7.7, P<0.001). MRD-positive patients who received ACT showed improved DFS compared to patients observed post-surgery (adjHR: 6.1, FDR adj P=0.0007). No ACT benefit was observed in MRD-negative patients (adj HR: 1.20, FDR adj P=0.768). On evaluating ctDNA dynamics from MRD to surveillance, patients who remained ctDNA-positive or converted from negative to positive showed a significantly inferior DFS (HR: 34.40, P<0.0001; HR: 13.65, P<0.0001) compared to persistently ctDNA-negative patients. Conclusions: Postsurgical ctDNA detection is prognostic of relapse and potentially predictive of ACT benefit in patients with resectable colon cancer, which may enable personalized surveillance, intervention, and/or trial options, ultimately improving patient outcomes.
Hyperoxia and End-Organ Complications Among Cardiogenic Shock Patients Supported by Venoarterial Extracorporeal Membrane Oxygenation
Wang, Jeffrey , Gangavelli, Apoorva , Tonna, Joseph E. , Magruder, J. Trent , Yalamuri, Suraj , Miller, P. Elliott , Tonna, Joseph E. , Wang, Jeffrey , Zaaqoq, Akram , Jentzer, Jacob C.

Mayo Clinic

Critical Care Medicine | August 6, 2025 | Volume: 53 | Issue: 10 | Pages: e2043-e2053

10.1097/ccm.0000000000006810 | PMID 40767559 Get It

OBJECTIVES: To investigate whether severe hyperoxia predisposes to end-organ complications and whether these complications contribute to in-hospital mortality among cardiogenic shock (CS) patients supported in venoarterial extracorporeal membrane oxygenation (VA-ECMO). DESIGN: Adult patients with CS from the Extracorporeal Life Support Organization Registry between 2010 and 2023 were categorized into normoxia (Pao 2 60–150 mm Hg), mild hyperoxia (Pao 2 151–300 mm Hg), and severe hyperoxia (Pao 2 > 300 mm Hg) based on their Pao 2 at 24 hours. The primary outcome was in-hospital mortality. End-organ complications were analyzed using multivariate logistic regression models, and causal mediation analysis was performed to estimate the direct and indirect effects of hyperoxia on mortality. SETTING: Multicenter, multinational prospective cohort study. PATIENTS: Adults with CS supported on VA-ECMO. INTERVENTIONS: Partial pressure of oxygen at 24 hours after VA-ECMO cannulation. MEASUREMENTS/MAIN RESULTS: A total of 10,541 patients were included (normoxia: 48.4%, mild hyperoxia: 30.0%, severe hyperoxia: 21.5%). There was higher in-hospital mortality in patients with severe hyperoxia (71.7%, adjusted OR [aOR]: 2.17; 95% CI, 1.19–2.50) and mild hyperoxia (63.8%, aOR: 1.34; 95% CI, 1.19–1.50) compared normoxia (52.7%; referent group). Severe hyperoxia was associated with more end-organ complications, which incrementally predicted higher mortality (aOR: 1.42; 95% CI, 1.25–1.61). Mediation analysis demonstrated that hyperoxia primary exerted a direct effect on mortality (86%), with contributions from neurologic (3.1%), hepatic (3.9%), renal (3.5%), and bleeding (2.3%) complications. CONCLUSIONS: Severe hyperoxia in patients with CS receiving VA-ECMO is associated with increased mortality and more end-organ complications. However, most of the effect of severe hyperoxia on mortality occurs via direct effects, independent of end-organ complications. These findings highlight the potential direct toxicity of hyperoxia and underscore the need for strategies to optimize oxygen delivery in this critically ill population.
Long‐Term Outcomes Following Left Atrial Appendage Occlusion in Medicare Beneficiaries: Outcomes From the National Cardiovascular Data Registry
Higgins, Angela Y. , Zimmerman, Sarah , Wang, Yongfei , Faridi, Kamil F. , Price, Matthew J. , Holmes, David R. , Curtis, Jeptha P. , Freeman, James V. , Friedman, Daniel J , Faridi, Kamil F , Price, Matthew J , Reddy, Vivek Y , Holmes, David R , Curtis, Jeptha P , Freeman, James V , Higgins, Angela Y. , Reddy, Vivek Y.

Mayo Clinic

Journal of the American Heart Association | August 6, 2025 | Volume: 14 | Issue: 16 | Pages: No page available

10.1161/jaha.124.039780 | PMID 40767285 Get It

Background Percutaneous left atrial appendage occlusion (LAAO) is an alternative to long‐term anticoagulation for preventing ischemic stroke in patients with atrial fibrillation. There are limited long‐term outcomes data for “real‐world” patients undergoing LAAO. Methods We performed a retrospective cohort study using the National Cardiovascular Data Registry LAAO registry from January 1, 2016, through December 31, 2019. We linked LAAO data to inpatient Medicare fee‐for‐service claims data using probabilistic matching to establish a cohort of patients 65 years and older undergoing LAAO with a WATCHMAN device. The primary outcomes were any stroke and all‐cause mortality. Results A total of 34 975 patients with a mean±SD CHA 2 DS 2 ‐VASc (congestive heart failure, hypertension, age ≥75 years, diabetes, previous stroke or transient ischemic attack, vascular disease, age 65 to 74 years, and sex category) score of 4.7±1.4 were included. The median follow‐up was 2.8 years (interquartile range, 2.2–3.7 years). The cumulative incidence of any stroke was 1.57 per 100 person‐years (95% CI, 1.45–1.70), with a 1‐year and 5‐year any stroke estimate of 1.70% (95% CI, 1.57–1.84%) and 5.70% (95% CI, 5.37–6.05%), respectively. The cumulative incidence of ischemic stroke was 1.36 per 100 person‐years (95% CI, 1.25–1.48), with a 1‐year and 5‐year ischemic stroke estimate of 1.42% (95% CI, 1.30–1.54%) and 5.03% (95% CI, 4.71–5.36%), respectively. The cumulative incidence of death was 10.82 per 100 person‐years (95% CI, 10.49–11.13), with a 5‐year mortality estimate of 44.34% (95% CI, 43.35–45.23%). Conclusions Long‐term stroke rates in a large nationally representative cohort of Medicare patients following LAAO were low and durably consistent during long‐term follow‐up despite a high thromboembolic risk. High mortality rates in this elderly population underscore the importance of incorporating patient values and preferences when considering LAAO.
Dynamic Fluid‐Assisted Continuous Multimaterial 3D Printing for Seamless Gradient Structures (Adv. Mater. Technol. 15/2025)
Wang, Wenbo , Liu, Siying , Liu, Luyang , Nogueira, Cauê , Ma, Xiaoli , Xu, Xin , Shefi, Orit , Lancaster, Jessica N. , Chen, Xiangfan

Mayo Clinic

Advanced Materials Technologies | August 6, 2025 | Volume: 10 | Issue: 15 | Pages: No page available

10.1002/admt.70217 Get It